DYN Q4 2025 Earnings — Dyne Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

DYNDyne Therapeutics, Inc.

$3B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$116M

Net Income

-$112M

EPS (Diluted)

$-0.69

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$112M

Free Cash Flow

-$112M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$215M

Stockholders' Equity

$972M

Cash & Equivalents

$893M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$116M	-$97M	-19.6%
Net Income	-$112M	-$90M	-25.0%